EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Inhibitors of SARS-CoV-2 Main Protease (Mpro) as Anti-Coronavirus Agents

Agnieszka Zagórska iD, Anna Czopek iD, Monika Fryc, Jakub Jończyk iD

Biomolecules · 04.07.2024 · 14 (7) · 797

DOI: 10.3390/biom14070797 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biomolecules, online erschienen am 04.07.2024. Verfasst von Agnieszka Zagórska und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland. Hauptthemen laut MEDLINE: SARS-CoV-2, Antiviral Agents, COVID-19 Drug Treatment, Coronavirus 3C Proteases. Die Arbeit wurde bisher 70-mal zitiert (Crossref) und nennt 116 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: THE POLISH NATIONAL AGENCY FOR ACADEMIC EXCHANGE, Polish National Agency for Academic Exchange.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The main protease (Mpro) of SARS-CoV-2 is an essential enzyme that plays a critical part in the virus’s life cycle, making it a significant target for developing antiviral drugs. The inhibition of SARS-CoV-2 Mpro has emerged as a promising approach for developing therapeutic agents to treat COVID-19. This review explores the structure of the Mpro protein and analyzes the progress made in understanding protein–ligand interactions of Mpro inhibitors. It focuses on binding kinetics, origin, and the chemical structure of these inhibitors. The review provides an in-depth analysis of recent clinical trials involving covalent and non-covalent inhibitors and emerging dual inhibitors targeting SARS-CoV-2 Mpro. By integrating findings from the literature and ongoing clinical trials, this review captures the current state of research into Mpro inhibitors, offering a comprehensive understanding of challenges and directions in their future development as anti-coronavirus agents. This information provides new insights and inspiration for medicinal chemists, paving the way for developing more effective Mpro inhibitors as novel COVID-19 therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2Antiviral AgentsCOVID-19 Drug TreatmentCoronavirus 3C ProteasesProtease InhibitorsHumansCOVID-19

Stichwörter der Autor:innen

3-chymotrypsin-like protease (3CLpro)COVID-19SARS-CoV-2anti-coronavirus agentsinhibitorsmain proteases (Mpro)protein-ligand interactions

Substanzen

Antiviral AgentsCoronavirus 3C ProteasesProtease Inhibitors

Autor:innen und Institutionen

  • Department of Medicinal Chemistry, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland.

ORCID-Profile: Agnieszka Zagórska, Anna Czopek, Jakub Jończyk

Förderung

  • THE POLISH NATIONAL AGENCY FOR ACADEMIC EXCHANGE
  • Polish National Agency for Academic Exchange

Zitieren

APA

Zagórska, A., Czopek, A., Fryc, M., & Jończyk, J. (2024). Inhibitors of SARS-CoV-2 Main Protease (Mpro) as Anti-Coronavirus Agents. Biomolecules, 14(7), 797. https://doi.org/10.3390/biom14070797

Vancouver

Zagórska A, Czopek A, Fryc M, Jończyk J. Inhibitors of SARS-CoV-2 Main Protease (Mpro) as Anti-Coronavirus Agents. Biomolecules. 2024;14(7):797. doi:10.3390/biom14070797

BibTeX
@article{Zagrska2024,
  author = {Zagórska, Agnieszka and Czopek, Anna and Fryc, Monika and Jończyk, Jakub},
  title = {Inhibitors of SARS-CoV-2 Main Protease (Mpro) as Anti-Coronavirus Agents},
  journal = {Biomolecules},
  year = {2024},
  volume = {14},
  number = {7},
  pages = {797},
  doi = {10.3390/biom14070797}
}
Kostenlos starten →